San Francisco, CA – According to filings with the U.S. Securities and Exchange Commission, Ambagon Therapeutics is raising $84,999,994.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Scott Clarke played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Ambagon Therapeutics
Ambagon is discovering and developing small molecule cancer drugs that stabilize the direct interaction of oncogenic proteins with the 14-3-3 class of adaptor proteins. Driven by the need for new therapeutic options for cancer patients, our team is harnessing our deep scientific expertise and drug discovery know-how to create first in class protein-protein interaction stabilizer drugs as novel targeted cancer treatments. Ambagons approach selectively augments the endogenous tumor suppression activity of 14-3-3 proteins bound to transcription factors and oncoproteins that have proven challenging to modulate with conventional approaches. Ambagons platform approach will also open opportunities to address other major unmet clinical needs.

To learn more about Ambagon Therapeutics, visit http://ambagontx.com/

Contact:
Scott Clarke, Chief Executive Officer
650-231-5131
sclarke@ambagontx.com
https://www.linkedin.com/in/scott-clarke-713a441/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved